Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss
NCT07389213, Not applicable, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss | ClinicalTrials.gov |
| NCT number | NCT07389213 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 189 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | ClinicalTrials.gov |
| Conditions | Senile Deadness | ClinicalTrials.gov |
| Interventions | repetitive Transcranial Magnetic Stimulation (rTMS) | ClinicalTrials.gov |
| First posted | 2026-02-05 | ClinicalTrials.gov |
| Last updated | 2026-02-05 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment(MoCA ) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Montreal Cognitive Assessment (MoCA) ranges from 0 to 30, with higher scores indicating better cognitive function; a score of 26 or above is generally considered normal. The overall cognitive function in all groups with hearing loss was assessed using the MoCA scale before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Mini-Mental State Examination(MMSE) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Mini-Mental State Examination (MMSE) is scored on a scale from 0 to 30, with higher scores indicating better cognitive function. Overall cognitive function was assessed in all groups using the MMSE before and after the intervention, and the change scores were calculated. | ClinicalTrials.gov |
| Secondary | Pure-Tone Average(PTA) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Pure-Tone Average (PTA) is calculated as the mean hearing threshold (in decibels hearing level, dB HL) at 500 Hz, 1 kHz, 2 kHz, and 4 kHz before and after intervention in the ARHL-HA group and the ARHL-nonHA group was assessed using pure-tone audiometry and sound field audiometry, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Speech Reception Threshold(SRT) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Speech Reception Threshold (SRT) is the lowest intensity levelat which a person correctly identifies 50% of spondaic (two-syllable) words were correctly identified before and after intervention in the ARHL-HA group and the ARHL-nonHA group was assessed using speech audiometry and sound field speech audiometry, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part A (TMT-A) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Trail Making Test Part A (TMT-A) is scored based on the time (in seconds) required to complete the task, with lower scores indicating better attention and information processing speed. The attention and information processing speed in the ARHL-HA group and the ARHL-nonHA group were assessed using the TMT-A before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part B (TMT-B) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Trail Making Test Part B (TMT-B) is scored based on the time (in seconds) required to complete the task, with lower scores indicating better set-shifting ability and executive function. The set-shifting component of executive function in the ARHL-HA group and the ARHL-nonHA group was assessed using the TMT-B before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Digit Span Test (DST)improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Digit Span Test (DST) is scored as the total number of correctly recalled digit sequences, with a typical total raw score ranging from 0 to 8. Higher scores indicate better attention, short-term memory, and working memory. Attention, short-term memory, and working memory in the ARHL-HA group and the ARHL-nonHA group were assessed using the DST before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Stroop Color and Word Test (SCWT) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Stroop Color and Word Test (SCWT) is typically scored based on the time (in seconds) required to complete specific conditions .Lower completion times or lower interference scores indicate better inhibitory control and faster information processing speed, meaning lower values represent a better outcome. The inhibitory control of dominant responses and information processing speed, as components of executive function, in the ARHL-HA group and the ARHL-nonHA group were assessed using the SCWT before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | 15-item Geriatric Depression Scale (GDS-15) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The 15-item Geriatric Depression Scale (GDS-15) is scored by summing the number of depressive symptom responses, with total scores ranging from 0 (no depressive symptoms) to 15 (most severe depressive symptoms). Higher scores indicate greater severity of depressive symptoms. Depressive symptom scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the GDS-15 before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | 24-item Hamilton Depression Rating Scale (HAMD-24)improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The 24-item Hamilton Depression Rating Scale (HAMD-24) is a clinician-administered measure of depressive symptom severity, with total scores ranging from 0 to 76. Higher scores indicate more severe depression. Depressive symptom scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the HAMD-24 before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) improvement value | Baseline、Post-intervention 2 weeks and Post-intervention 1 month | The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a one-month period. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. Sleep scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the PSQI before and after intervention, and the difference was calculated. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)